Inhibrx Biosciences, Inc. Common Stock (INBX) Stock
Key stats
- Market cap
- $1.33B
- Price / Earnings ratio
- -9.7x
- EPS (TTM)
- -$8.88
- Volume
- Loading
- 52-week high
- $155.29
- 52-week low
- $57.30
Source: third-party data provider, as of November 13, 2026
Compare with INBX
Recent news

Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
INBX

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
INBX

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
INBX

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
INBX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.68
- MACD 12/26/9
- -2.32
- EMA 9 of MACD
- -3.94
- MACD histogram
- 1.61
- SMA 50
- $96.79
- Price below SMA 50
- EMA 50
- $92.46
- Price below EMA 50
- SMA 200
- $92.57
- Price below SMA 200
- EMA 200
- $91.09
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
INBX

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
INBX

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
INBX

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
INBX

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
INBX

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
INBX

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
INBX

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
INBX

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
INBX

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
INBX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Inhibrx Biosciences, Inc. Common Stock
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark Paul Lappe | Founder, CEO & Chairman | 1967 |
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive VP, CFO & Treasurer | 1980 |
| Mr. David J. Matly M.B.A. | President | 1986 |
| Ms. Bonne Adams M.B.A. | Vice President of Operations | 1977 |
| Ms. Kate Burke CPA, M.B.A. | Vice President of Accounting | — |
| Dr. Ashraf Amanullah Ph.D. | Executive VP & Chief Technical Operations Officer | 1968 |
| Dr. Carlos Bais Ph.D. | EVP & Chief Scientific Officer | — |
| Ms. Leah Pollema J.D. | VP, General Counsel & Corporate Secretary | — |
| Dr. Josep Garcia Ph.D. | Executive VP & Chief Clinical Development Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.68
- MACD 12/26/9
- -2.32
- EMA 9 of MACD
- -3.94
- MACD histogram
- 1.61
- SMA 50
- $96.79
- Price below SMA 50
- EMA 50
- $92.46
- Price below EMA 50
- SMA 200
- $92.57
- Price below SMA 200
- EMA 200
- $91.09
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $245.00
- Average
- $245.00
- High
- $245.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.1 | -19.2 | -4.6 | -13.6 | +53.2 | -19.7 | -26.7 | +25.5 |



